Competition in the anti-neoplastic agents market is shaped by research capabilities, clinical development pipelines, product differentiation, and regulatory expertise. Pharmaceutical companies invest in novel compounds, biologic therapies, and expanded indications for established medicines. Long-term competitiveness depends on clinical evidence, treatment suitability, manufacturing reliability,...